<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neurol Neuroimmunol Neuroinflamm</journal-id>
<journal-id journal-id-type="iso-abbrev">Neurol Neuroimmunol Neuroinflamm</journal-id>
<journal-id journal-id-type="hwp">nnn</journal-id>
<journal-id journal-id-type="publisher-id">NEURIMMINFL</journal-id>
<journal-title-group>
<journal-title>Neurology® Neuroimmunology &amp; Neuroinflammation</journal-title>
</journal-title-group>
<issn pub-type="epub">2332-7812</issn>
<publisher>
<publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>
<publisher-loc>Hagerstown, MD</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30175165</article-id>
<article-id pub-id-type="pmc">6117192</article-id>
<article-id pub-id-type="publisher-id">NEURIMMINFL2017015800</article-id>
<article-id pub-id-type="doi">10.1212/NXI.0000000000000491</article-id>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>41</subject>
<subject>323</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Identification of MS-specific serum miRNAs in an international multicenter study</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Regev</surname>
<given-names>Keren</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>Commercial advisory board - Merck Commercial advisory board - Sanofi Commercial advisory board - Biogen</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for travel or speaker honoraria:</title>
<list-item>
<p>Travel Grant by Merck Travel Grant by Roch Travel Grant by Biogen</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Healy</surname>
<given-names>Brian C.</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>(1) Biogen Worldwide Medical Biostatistics Multiple Sclerosis Advisory Board.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>(1) Statistical methods in medical research, editorial board, 2007-present</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>(1) Merck Serono, S.A. (2) Novartis (3) Genzyme (4) Verily Life Sciences</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>(1) NIH, 1UL1TR001102-07, Biostatistician, 2013-present (2) NIH, 1UH2TR000890-01, Biostatistician, 2013-present (3) NIH, 5R01HL113272-02, Biostatistician, 2013-present</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Paul</surname>
<given-names>Anu</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Diaz-Cruz</surname>
<given-names>Camilo</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>Merck Serono, Verily Life Sciences</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mazzola</surname>
<given-names>Maria Antonietta</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Raheja</surname>
<given-names>Radhika</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Glanz</surname>
<given-names>Bonnie I.</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>Merck Serono SA, co-investigator, 2009-2016 Verily Life Sciences, co-investigator, 2015-2017</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>(1)NIH, R01N5087226-01A1, Co-I, 2014-19 (2)NIH, 1UH2TR000890-01, Co-I, 2013-15</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>Brigham Research Institute, Co-PI, 2017-2018</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NMSS, PI, 2015-16 CMSC, PI, 2017-18</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kivisäkk</surname>
<given-names>Pia</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>Research support from Genentech, Sanofi Genzyme, and Verily Life Sciences.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chitnis</surname>
<given-names>Tanuja</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>Dr. Chitnis has served on clinical trial advisory boards for Novartis Pharmaceuticals, and Genzyme-Sanofi.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>Dr. Chitnis has served as a one-time consultant for Biogen, Celgene, Novartis and Sanofi-Genzyme</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>Dr. Chitnis receives research support from (1) EMD- Serono, (2) Verily, in the form of Independent Investigator Awards.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NIH</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>Dr. Chitnis receives research support from the National Multiple Sclerosis Society, the Peabody Foundation, the Consortium for MS Centers and the Guthy-Jackson Charitable Foundation.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jagodic</surname>
<given-names>Maja</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>(1) Physiological Genomics, Editorial Board member, 2015- present (2) Frontiers in Neurology, Associate Editor, 2017-present</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>(1) AstraZeneca (AstraZeneca-Science for Life Laboratory collaboration), co-investigator, 2014-2018</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>(1) The Swedish Research Council, lead investigator, K2015-61X-20776-08-3, 2015-2018 (2) The regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet, SLL20150206, lead investigator, 2016-2017 (3) The regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet, SLL20170532, lead investigator, 2018-2020</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>(1) The Swedish Association for Persons with Neurological Disabilities, co-investigator (2) The Swedish Brain Foundation, main investigator (3) The Swedish Medical Society, main investigator (4) Petrus and Augusta Hedlunds Foundation, main investigator</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Piehl</surname>
<given-names>Fredrik</given-names>
</name>
<degrees>MD, PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>data safety monitoring committee Parexel/Chugai, outside of this study</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>1. Biogen - unrestricted academic research projects outside of this study 2. Novartis - unrestricted academic research projects outside of this study 3. Genzyme - unrestricted academic research projects outside of this study</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>Swedish Medical Research Council (grant 2017-03054) PI, 2018- ongoing. Pcori, Washington DC (grant MS-1511-33196) PI, 2017- ongoing</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Olsson</surname>
<given-names>Tomas</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>Advisory boards Biogen 2006- 2018 and Genzyme 2006- 2018, Merck 2016-2018. Novartis 2009-2018. With all of them advice with regard to therapy in multiple sclerosis</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for travel or speaker honoraria:</title>
<list-item>
<p>For lectures on Multiple sclerosis, Novartis 2008 and BiogenIdec 2006, 2007, 2008, 2009, 2010 , 2011, 2012 and 2016. Genzyme 2012 and 2013. Merck 2017</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>Co-editor 2006 in Current opinion in Immunology</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>1)Merck, 2)Biogen, 3)Genzyme, 4) Novartis, 5) Roche and 6) Merck, all for unrestricted MS research.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>Tomas Olsson (TO) has received grant support from The Swedish Research council (07488), EU fp7, Neurinox 2012-2016 and combiMS, 2013-2014, Swedish Brain foundation, Knut and Alice Wallenberg foundation.Margareta af Ugglas foundation</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>The Knut and Allice Wallenberg foundation, The Swedish Brain foundation . TO has also received unrestricted research grants from Bayer Schering, Genzyme/Sanofi-AventisBiogen Idec and AstraZeneca.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Khademi</surname>
<given-names>Mohsen</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hauser</surname>
<given-names>Stephen</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>Serves on scientific advisory board for (1) Symbiotix, (2) Annexon, (3) Bionure, and (4) Molecular Stethoscope (5)Alector; serves on Board of Trustees for (6) Neurona.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for travel or speaker honoraria:</title>
<list-item>
<p>(1) F. Hoffmann La Roche; travel reimbursement for anti-CD20 related meetings and presentations.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>(1) Harrison's Principles of Internal Medicine, McGraw-Hill Education, 2016</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other activities:</title>
<list-item>
<p>(1) F. Hoffmann La Roche; writing support for anti-CD20 related presentations.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>(1) NIH, RO1NS026799, PI; RO1NS092835, PI;</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>(1) National Multiple Sclerosis Society, RG 2899; (2) Conrad N. Hilton Foundation</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Oksenberg</surname>
<given-names>Jorge</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>Genes and Immunity. Editorial Board, 1999-present</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>University of California at San Francisco</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>192333 (Oksenberg) 07/01/2015 ? 07/01/2019 0.32 cal mos Genentech, Inc. $623,689 DC/yr Predictors of progression and neurological disability in multiple sclerosis Major goal: To understand the biological determinants of disease progression in multiple sclerosis that correlate with neuroinflammation, myelin injury and neuronal loss. Role: Principal Investigator</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>U19NS095774 (Oksenberg/Fernandez-Vina) 07/01/2015 ? 06/30/2020 3.00 cal mos NIH/NIAID $1,095,786 DC/yr Immunogenetic Determinants of Disease Risk in Neurological Disease Major Goal: The goal of this project is to perform high-resolution HLA and KIR next generation sequencing-based genotyping and analysis in multiple neurological diseases. Role: Co-Principal Investigator R01NS026799 (Hauser/Oksenberg) 9/30/2015 ? 7/31/2019 1.92 cal mos NIH/NINDS $268,125 DC/yr Gene Linkage Study of Multiple Sclerosis Sibling Pairs Major Goal: Our proposal harnesses the power of neuroimaging information to bridge genetics with clinical expression of the disease (i.e. the phenotype), representing therefore an important step to promote evidence-based personalized medicine in a complex neurological disease. Role: Co-Principal Investigator R01NS088155 (Baranzini) 09/15/2014 ? 07/31/2019 0.60 cal mos NIH/NINDS $262,065 DC/yr Post GWAS approach to identify cell-specific genetic pathways underlying MS risk Major Goal: The goal of this project is to identify and characterize cell-specific QTLs in multiple sclerosis and to perform a comprehensive analysis of gene x gene interactions underlying susceptibility. Role: Co-Investigator R01NS096212 Subcontract (Oksenberg) 08/01/2016 ? 05/31/2021 0.60 cal mos University of Miami $23,086 DC/yr Genetic and phenotypic analysis of multiple sclerosis in Hispanics Major Goal: To perform a genome-wide genetic screen in a Hispanic multiple sclerosis cohort. Role: Subcontract Principal Investigator R01NS102153 (Oksenberg-Hollenbach) 07/01/2017 ? 06/30/2022 1.80 cal mos MHC variation at high resolution in multiple sclerosis $440,491 DC/yr Major Goal: We propose to fully describe the nature and extent of MHC variation in multiple sclerosis through sophisticated sequencing and gene editing methods applied to large and well-characterized cohorts. Role: Co-Principal Investigator</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>RG 2899-D11 (Oksenberg/Hauser) 07/01/2012-12/30/2017 (NCE) 0.6 cal mos National Multiple Sclerosis Society$309,870 DC/yr Establishment of a Core DNA Repository for Multiple Sclerosis Major Goal: The objectives of this grant are to maintain and expand a core DNA repository of multiple sclerosis patients and family members. To maintain and expand a centralized relational database system for the storage and pairing of clinical, demographic, repository and laboratory generated data. Role: Principal Investigator RG-1607-25103 (Graves) 04/01/2017 ? 03/31/2020 0.6 cal mos National Multiple Sclerosis Society $326,464 DC/yr The role of biological aging on progression in MS Major Goal: to address the hypothesis that MS progression is an aging-related disease by assessing associations of biomarkers of aging leukocyte telomere length and a genetic risk score for telomere length) and sex specific markers of aging (anti-Mullerian hormone for ovarian aging, testosterone for male aging) with clinical and imaging correlates of disease progression. Role: Co-Investigator</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Khoury</surname>
<given-names>Samia J.</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>Annals of Neurology-Associate Editor Clinical immunology-Section editor Current Treatment Options in Neurology-Editorial Board MS Journal- Editorial Board</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>Investigator Initiated trial support from Novartis-Unrelated study</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Weiner</surname>
<given-names>Howard L.</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>served on the advisory board for The Guthy Jackson Charitable Foundation, Teva Pharmaceutical Industries Ltd., Biogen Idec, Novartis, Sanofi-aventis, Tilos Therapeutics, CBridge Capital, Genentech, Genzyme, vTv Therapeutics, MedDay Pharmaceuticals</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>Biodextris Biogen Novartis Serono Teva Sanofi Genzyme Tilos Therapeutics Tiziana Life Sciences vTv Therapeutics MedDay Pharmaceuticals Genentech CBridge Capital</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>EMD Serono Google Life Sciences</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NIH UH3TR000890 - PI - 08/01/13 ? 07/31/18 R01 NS087226 - PI - 09/30/14 ? 07/31/19 R01 EY027921 - PI - 09/01/17 ? 08/31/20</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>National Multiple Sclerosis Society</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Gandhi</surname>
<given-names>Roopali</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>I am employed by Sanofi Genzyme, AssociateMedical Director, starting from September 2017</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>(1) Sanofi Genzyme</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NIH, UH2/UH3 000890-01, Co-PI, 5 years</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>Race to Erase MS</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<aff>From the Partners Multiple Sclerosis Center (K.R., B.C.H., A.P., M.A.M., R.R., P.K., T.C., H.L.W., R.G.), Brigham and Women's Hospital; Department of Neurology, Harvard Medical School (B.C.H., C.D.-C., B.I.G., T.C., H.L.W, R.G.), Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital; Biostatistics Center (B.C.H.); Massachusetts General Hospital, Boston, MA; Department of Clinical Neuroscience, Neuroimmunology Unit (M.J., F.P., T.O., M.K.), Karolinska Institute, Stockholm, Sweden; Department of Neurology (S.H., J.O.), School of Medicine, University of California, San Francisco; and Nehme and Therese Tohme Multiple Sclerosis Center (S.J.K.), Faculty of Medicine, American University of Beirut Medical Center, <country>Lebanon.</country></aff>
</contrib-group>
<author-notes>
<corresp><bold>Correspondence</bold> Dr. Gandhi <email>rgandhibwh@gmail.com</email></corresp>
<fn fn-type="other">
<p>Authors in the SUMMIT Consortium are listed at <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/NXI/A75">http://links.lww.com/NXI/A75</ext-link>.</p>
</fn>
<fn fn-type="financial-disclosure">
<p>Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at <ext-link ext-link-type="uri" xlink:href="http://nn.neurology.org/lookup/doi/10.1212/NXI.0000000000000491">Neurology.org/NN</ext-link>.</p>
</fn>
<fn fn-type="other">
<p>The Article Processing Charge was funded by NIH, UH3TR000890.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>20</day>
<month>8</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>20</day>
<month>8</month>
<year>2018</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>5</volume>
<issue>5</issue>
<elocation-id>e491</elocation-id>
<history>
<date date-type="received">
<day>13</day>
<month>1</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>6</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>American Academy of Neurology</copyright-holder>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p>
</license>
</permissions>
<self-uri xlink:href="NEURIMMINFL2017015800.pdf" xlink:title="pdf"></self-uri>
<abstract>
<sec>
<title>Objective</title>
<p>To identify circulating microRNAs (miRNAs) linked to disease, disease stage, and disability in MS across cohorts.</p>
</sec>
<sec>
<title>Methods</title>
<p>Samples were obtained from the Comprehensive Longitudinal Investigation of Multiple Sclerosis (CLIMB, Boston, MA), EPIC (San Francisco, CA), AMIR (Beirut, Lebanon) as part of the SUMMIT consortium, and Stockholm Prospective Assessment of Multiple Sclerosis (Stockholm, Sweden) cohorts. Serum miRNA expression was measured using locked nucleic acid–based quantitative PCR. Four groups were compared: (1) MS vs healthy control (HC), (2) relapsing-remitting (RR) vs HC, (3) secondary progressive (SP) vs HC, and (4) RR vs SP. A Wilcoxon rank-sum test was used for the comparisons. The association between each miRNA and the Expanded Disability Status Scale (EDSS) score was assessed using the Spearman correlation coefficient. For each comparison, the <italic>p</italic> values were corrected for multiple comparisons using the approach of Benjamini and Hochberg to control the false discovery rate.</p>
</sec>
<sec>
<title>Results</title>
<p>In the CLIMB cohort, 5 miRNAs (hsa-miR-484, hsa-miR-140-5p, hsa-miR-320a, hsa-miR-486-5p, and hsa-miR-320c) showed a significant difference between patients with MS and healthy individuals; among these, miR-484 remained significant after accounting for multiple comparisons (<italic>p</italic> = 0.01). When comparing RRMS with HCs, hsa-miR-484 showed a significant difference (<italic>p</italic> = 0.004) between the groups after accounting for multiple group comparisons. When SP and HC were compared, 6 miRNAs (hsa-miR-484, hsa-miR-140-5p, hsa-miR-142-5p, hsa-miR-320a, hsa-miR-320b, and hsa-miR-320c) remained significantly different after accounting for multiple comparisons. Disability correlation analysis with miRNA provided 4 miRNAs (hsa-miR-320a, hsa-miR-337-3p, hsa-miR-199a-5p, and hsa-miR-142-5p) that correlated with the EDSS during the internal reproducibility phase. Among these, hsa-miR-337-3p was the most statistically significant miRNA that negatively correlated with the EDSS in three of the MS cohorts tested.</p>
</sec>
<sec>
<title>Conclusions</title>
<p>These findings further confirm the use of circulating serum miRNAs as biomarkers to diagnose and monitor disease status in MS.</p>
</sec>
<sec>
<title>Classification of evidence</title>
<p>This study provides Class III evidence that levels of circulating miRNAs identify patients with MS.</p>
</sec>
</abstract>
<funding-group>
<award-group>
<funding-source>NIH</funding-source>
<award-id>TR000890</award-id>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>OPEN-ACCESS</meta-name>
<meta-value>TRUE</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<p>MS is an autoimmune disorder that attacks the CNS.<sup><xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R2">2</xref></sup> The disease course of MS is extremely variable<sup><xref ref-type="bibr" rid="R3">3</xref>,<xref ref-type="bibr" rid="R4">4</xref></sup>; this diversity in the disease phenotype is not well correlated with currently used biomarkers; thus, there is an urgent need for efficacious diagnostic assays for MS detection, prognostic measures of disease progression, and treatment response.</p>
<p>Research on circulating biomarkers has yielded some promising candidates for MS detection including glycoproteins, chemokines, antibodies, lipopeptides, and genetic polymorphisms. More recently, microRNAs (miRNAs) have been investigated as potential biomarkers in MS.<sup><xref ref-type="bibr" rid="R5">5</xref><xref ref-type="bibr" rid="R6">–</xref><xref ref-type="bibr" rid="R8">8</xref></sup> miRNAs constitute particularly exciting biomarker candidates because they are very stable molecules, and their differential expression in circulating fluids (e.g., blood) has been shown to correlate with many disease states, including MS.<sup><xref ref-type="bibr" rid="R5">5</xref></sup></p>
<p>Recently, our laboratory identified a set of serum miRNAs as potential diagnostic MS biomarkers.<sup><xref ref-type="bibr" rid="R9">9</xref></sup> Differential expression of 7 miRNAs in MS vs healthy controls (HCs) was validated during a 2-year comprehensive discovery and validation study. In addition, we reported 10 miRNAs that significantly correlated with patient disability status as measured by the Expanded Disability Status Scale (EDSS).<sup><xref ref-type="bibr" rid="R9">9</xref></sup></p>
<p>In the current study, we tested the reproducibility of our previous findings using patients with MS and HCs from the Comprehensive Longitudinal Investigation of Multiple Sclerosis (CLIMB) cohort. In addition, we tested the transportability of our results in MS samples collected from three other international MS collections including the SUMMIT consortium (San Franciso and Beirut) and the STOPMS II study (Stockholm).</p>
<p>This study design using patient samples from multiple centers (n = 259) was implemented to identify the most promising serum miRNA biomarker candidates for MS diagnosis and disability status.</p>
<sec id="s1" sec-type="methods">
<title>Methods</title>
<sec id="s1-1">
<title>Study design</title>
<p>The study involved multiple phases: (1) discovery, (2) validation, (3) reproducibility, and (4) transportability phases (figure e-1, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/NXI/A63">links.lww.com/NXI/A63</ext-link>). The first 2 phases of the study have been described previously.<sup><xref ref-type="bibr" rid="R9">9</xref></sup> These phases are summarized as follows:<list list-type="order"><list-item><p>Discovery: 652 miRNAs were measured in participants from 3 groups: RRMS (n = 7), SPMS (n = 9), and HC (n = 20).<sup><xref ref-type="bibr" rid="R9">9</xref></sup></p></list-item><list-item><p>Validation: based on the findings observed in the discovery phase, 191 miRNAs were measured in a larger validation set of participants from CLIMB patients: RRMS (n = 29), SPMS (n = 19), and HC (n = 30), including an additional cohort of participants with either other inflammatory diseases or other neurodegenerative diseases.<sup><xref ref-type="bibr" rid="R9">9</xref></sup> This phase was used as the training set for a multivariate approach using predictive models.</p></list-item><list-item><p>Reproducibility phase: 73 miRNAs showing promise to serve as biomarkers<sup><xref ref-type="bibr" rid="R9">9</xref></sup> were further analyzed in a reproducibility phase with RRMS (n = 24), SPMS (n = 18), and HC (n = 30) from the CLIMB cohort. This phase was used as the test set for the predictive models that were designed in the validation (training phase).</p></list-item><list-item><p>Transportability phase: the 73 miRNAs from the reproducibility phase were further analyzed in 3 external cohorts with study participants from 3 MS centers worldwide: RRMS (n = 91), SPMS (n = 33), and HC (n = 58).</p></list-item></list></p>
</sec>
<sec id="s1-2">
<title>Patient selection</title>
<p>For the reproducibility phase, a new group of participants from the CLIMB cohort was identified. In addition to this new group of CLIMB participants, 3 external cohorts were included in the study. The first cohort was from the AUBMC-Multiple Sclerosis Interdisciplinary Research cohort of the American University of Beirut Medical Center—Abou Haidar Neuroscience Institute; 31 patients with RRMS, 5 patients with SPMS, and 19 HCs were included in the study. The second cohort was from the EPIC (Expression/genomics, Proteomics, Imaging, Clinical) cohort of the University of California at San Francisco<sup><xref ref-type="bibr" rid="R10">10</xref></sup>; 27 patients with RRMS, 7 patients with SPMS, and 26 HCs were included in the study. The third cohort was from the STOPMS II (Stockholm Prospective Assessment of Multiple Sclerosis) cohort of Sweden; 33 patients with RRMS, 21 patients with SPMS, and 13 HCs were included in the study.</p>
<p>The demographic characteristics of all 4 cohorts are provided in <xref ref-type="table" rid="T1">table 1</xref>. None of the selected patients were on any disease-modifying treatment at the time of sample collection.</p>
<table-wrap id="T1" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<p>Patient demographics</p>
</caption>
<graphic xlink:href="NEURIMMINFL2017015800t1"></graphic>
</table-wrap>
</sec>
<sec id="s1-3">
<title>Standard Protocol Approvals, Registrations, and Patient Consents</title>
<p>Written informed consent was obtained from all patients, and regional ethical committees approved the study (CLIMB cohort, IRB Protocol No: 1999P010435; EPIC cohort, IRB Protocol No: 10-00104; AMIR cohort, IRB Protocol No: IM.SK1.01; and STOPMS II cohort, IRB Protocol No: 2010/2:1).</p>
</sec>
<sec id="s1-4">
<title>Sample collection and storage</title>
<p>Blood samples were collected in glass red top serum vacutainer tubes without additives (Becton, Dickinson and Company, Franklin Lakes, NJ), and serum tubes were kept at room temperature for 30–60 minutes. Each sample was centrifuged at 2000 RPM for 10 minutes to separate the serum and then stored at −70°C until RNA extraction. Freezing of the serum occurred within 2 hours of the blood draw. Serum samples from the external cohorts were sent to Boston for further processing.</p>
</sec>
<sec id="s1-5">
<title>RNA extraction and analysis</title>
<p>RNA was isolated using the miRCURY kit (Exiqon, Waltham, MA) and converted to cDNA using a synthesis kit from Exiqon following the manufacturer's instructions. Prepared cDNAs were stored at −20°C until use. LNA SYBR green–based real-time PCR was used to detect the expression of selected miRNAs (Exiqon). Normalization was performed using the mean expression of the miRNAs with the best stability index, i.e., showing expression stability in our sample set. NormFinder software was used to calculate the stability index. We used 5 normalizing miRNAs (hsa-miR-484, hsa-miR-30e-5p, hsa-miR-590-5p, hsa-let-7d-3p, and hsa-miR-15b-5p). The formula used to calculate the normalized Cq values is as follows: <inline-formula><inline-graphic xlink:href="NEURIMMINFL2017015800mu1.jpg"></inline-graphic></inline-formula>.</p>
</sec>
<sec id="s1-6">
<title>Statistical analysis</title>
<p>In the CLIMB cohort, 4 groups were compared for each miRNA: (1) all MS vs HC, (2) relapsing-remitting (RR) vs HC, (3) secondary progressive (SP) vs HC, and (4) RR vs SP, and a Wilcoxon rank-sum test was used for the comparisons. For the Wilcoxon rank-sum test, participants that had no measured expression were assigned a value below the smallest available measurement so that these participants had the smallest rank for all analyses. In addition to the group comparisons, the association between each miRNA and the EDSS score was assessed using the Spearman correlation coefficient. For each comparison, the <italic>p</italic> values for miRNAs that passed validation were corrected for multiple comparisons using the approach of Benjamini and Hochberg<sup><xref ref-type="bibr" rid="R11">11</xref></sup> to control the false discovery rate (FDR).</p>
<p>We also compared the miRNA expression level between the groups using a proportional odds model to adjust for age and sex. The proportional odds model is a generalization of the Wilcoxon rank-sum test that allows adjustment for other variables.</p>
<p>In addition to the individual miRNA comparisons, prediction models were developed in the validation cohort (training set). The prediction models were built using all miRNAs that were in the same direction in the discovery and validation phases of the study using best subset regression with 3 miRNAs in the model. Three miRNAs were chosen, given the sample size limitations in the validation set (training set). The models were evaluated using the area under the ROC curve (AUCROC) in both the validation cohort (training set) and the reproducibility cohort (test set) to estimate the ability of the model to discriminate between the 2 groups. The estimated AUCROC from the reproducibility phase of the CLIMB cohort provides a more reliable estimate because data used in this set were not used in model building. In addition to best subset regression, several other approaches were used to build prediction models including stepwise selection, lasso, decision trees, and random forests, and the predictive performance of these approaches in our test set was assessed.</p>
<p>All analyses performed in the CLIMB cohort were completed in the 3 additional MS centers' cohorts during transportability phase. The miRNAs that showed significant differential expression or a significant association with the EDSS in multiple cohorts were identified. Furthermore, the AUCROC for each of the predictive models built in the CLIMB validation cohort (training set) was calculated for each external test set.</p>
</sec>
<sec id="s1-7">
<title>Data availability</title>
<p>Anonymized data not provided in the article because of space limitation will be shared upon request of other qualified investigators.</p>
</sec>
</sec>
<sec id="s2" sec-type="results">
<title>Results</title>
<sec id="s2-1">
<title>Reproducibility of biomarkers in the CLIMB cohort</title>
<p>The miRNAs that qualified the validation of the comparison between MS and HC in the CLIMB cohort with <italic>p</italic> &lt; 0.05 were tested during the reproducibility phase (<xref ref-type="table" rid="T2">table 2</xref>). Five previously validated miRNAs, namely, hsa-miR-484, hsa-miR-140-5p, hsa-miR-320a, hsa-miR-486-5p, and hsa-miR-320c, showed a significant difference, and 1 miRNA remained significant after accounting for multiple comparisons (hsa-miR-484, <italic>p</italic> = 0.01). When multiple miRNAs were included in a predictive model for MS vs HC, the miRNAs included were hsa-let-7c-5p, hsa-miR-452-5p, and has-miR-484. The AUCROC for this model in the validation cohort was 0.85, whereas the AUCROC in the reproducibility phase was 0.70 (figure e-2, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/NXI/A63">links.lww.com/NXI/A63</ext-link>). When the other model building approaches were used, the AUCROC in the reproducibility cohort ranged from 0.67 to 0.71.</p>
<table-wrap id="T2" orientation="portrait" position="float">
<label>Table 2</label>
<caption>
<p>Differential expression of significant miRNAs during the reproducibility phase (MS vs healthy controls)</p>
</caption>
<graphic xlink:href="NEURIMMINFL2017015800t2"></graphic>
</table-wrap>
<p>The comparisons of the miRNAs between RR and HC are provided in (table e-1, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/NXI/A64">links.lww.com/NXI/A64</ext-link>). In this comparison, only hsa-miR-484 showed a significant difference (<italic>p</italic> = 0.004) between the groups after accounting for multiple comparisons. When best subset regression was used to select a model for this comparison, the miRNAs included in the model were hsa-miR-15b-3p, hsa-miR-451a, and hsa-miR-584-5p. The AUCROC for this model in the validation set was 0.82, whereas the AUCROC in the reproducibility phase was 0.68 (figure e-3, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/NXI/A63">links.lww.com/NXI/A63</ext-link>). When the other model building approaches were used, the AUCROC in the validation ranged from 0.63 (decision tree) to 0.68 (best subset regression).</p>
<p>When SP and HC were compared (table e-2, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/NXI/A64">links.lww.com/NXI/A64</ext-link>), 8 miRNAs were significantly different, and 6 miRNAs (hsa-miR-484, hsa-miR-140-5p, hsa-miR-142-5p, hsa-miR-320a, hsa-miR-320b, and hsa-miR-320c) were significantly different after accounting for multiple comparisons. The miRNAs included in the model selected by best subset regression were hsa-let-7c-5p, hsa-miR-320a, and hsa-miR-424-5p. The AUCROC for this model in the validation was 0.99, whereas the AUCROC in the reproducibility phase was 0.71 (figure e-4, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/NXI/A63">links.lww.com/NXI/A63</ext-link>). When the other model building approaches were used, the AUCROC in the validation ranged from 0.71 (best subsets) to 0.75 (random forests).</p>
<p>When RR and SP were compared (table e-3, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/NXI/A64">links.lww.com/NXI/A64</ext-link>), no previously validated miRNAs were significantly different between the groups. When best subset regression was used to build a model, the miRNAs included in the model were hsa-miR134-5p, hsa-miR-337-3p, and hsa-miR-532-3p. The AUCROC for this model in the validation was 0.93, whereas the AUCROC in the reproducibility phase was 0.63 (figure e-5, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/NXI/A63">links.lww.com/NXI/A63</ext-link>). When the other model building approaches were used, the AUCROC in the validation ranged from 0.53 (decision tree) to 0.72 (lasso).</p>
<p>For the disability biomarkers, the miRNAs that were significantly correlated with the EDSS in validation as published in Regev et al. 2016<sup><xref ref-type="bibr" rid="R9">9</xref></sup> were further measured in reproducibility phase cohort. We found that 4 miRNA, hsa-miR-320b, hsa-miR-337-3p, hsa-miR-199a-5p, and hsa-miR-142-5p (<xref ref-type="table" rid="T3">table 3</xref>), were significantly correlated with the EDSS in the reproducibility phase cohort.</p>
<table-wrap id="T3" orientation="portrait" position="float">
<label>Table 3</label>
<caption>
<p>Correlation of significant miRNAs in association with Expanded Disability Status Scale in the reproducibility phase</p>
</caption>
<graphic xlink:href="NEURIMMINFL2017015800t3"></graphic>
</table-wrap>
</sec>
<sec id="s2-2">
<title>Transportability of biomarkers in external MS cohorts</title>
<p>When the additional cohorts were analyzed, a modest number of miRNAs showed significant differential expression in the same direction in multiple cohorts (<xref ref-type="table" rid="T4">table 4</xref>). For the comparison of MS and HC, 5 miRNAs were found to be differentially expressed in 2 of the 4 MS cohorts: hsa-let-7e-5p (AMIR and STOPMS II), hsa-let-7f-5p (CLIMB and STOPMS II), hsa-miR-486-5p (CLIMB and STOPMS II), and hsa-miR-30e-5p (CLIMB and EPIC) (<xref ref-type="table" rid="T4">table 4</xref>).</p>
<table-wrap id="T4" orientation="portrait" position="float">
<label>Table 4</label>
<caption>
<p>miRNAs showing significant association/differential expression during the transportability phase</p>
</caption>
<graphic xlink:href="NEURIMMINFL2017015800t4"></graphic>
</table-wrap>
<p>For the comparison of RR and HC, 2 miRNAs were differentially expressed in 2 of the 4 MS cohorts: hsa-let-7e-5p (AMIR and STOPMS II) and hsa-let-7f-5p (CLIMB and STOPMS II) (<xref ref-type="table" rid="T4">table 4</xref>). For the comparison of SP and HC, has-miR-320a, hsa-miR-320b, hsa-miR-320c, and hsa-miR-486-5p were differentially expressed in the CLIMB and STOPMS II cohorts (<xref ref-type="table" rid="T4">table 4</xref>).</p>
<p>When comparing the 4 cohorts in terms of association with the EDSS score, a statistically significant negative correlation with hsa-miR-337-3p was observed in 3 (CLIMB, AMIR and EPIC) of the cohorts. An additional 5 miRNAs (hsa-miR-142-5p, hsa-miR-199a-5p, hsa-miR-330-3p, hsa-miR-194-5p, and hsa-miR-941) showed a significant correlation in 2 of the cohorts (<xref ref-type="table" rid="T4">table 4</xref>).</p>
<p>When the prediction models from the CLIMB validation were applied to the transportability phase cohorts, the performance of the models was generally poor for most of the comparisons performed. The best performance was observed in the STOPMS II cohort for the SP vs HC comparisons (AUCROC = 0.73 for best subset model and AUCROC = 0.81 for random forests).</p>
</sec>
<sec id="s2-3">
<title>hsa-miR-337-3p as a marker for disability in MS</title>
<p>The expression of hsa-miR-337-3p negatively correlated with the EDSS in the discovery set of n = 85 (rs = −0.34; <italic>p</italic> = 0.0002) and the validation phases of n = 58 (rs = −0.30; <italic>p</italic> = 0.02).<sup><xref ref-type="bibr" rid="R9">9</xref></sup> These findings were further tested in another set of samples obtained from the CLIMB study (reproducibility phase) and in collaboration with 2 other international MS centers during the transportability phase (<xref ref-type="fig" rid="F1">figure 1</xref>). Results from these validation studies confirmed that hsa-miR-337-3p is negatively correlated with the EDSS in 3 of 4 cohorts as summarized in <xref ref-type="fig" rid="F1">figure, B</xref>.</p>
<fig id="F1" orientation="portrait" position="float">
<label>Figure</label>
<caption>
<title>Correlation between the Kurtzke Expanded Disability Status Scale and the relative expression of hsa-miR-337-3p</title>
<p>(A) Reproducibility phase: Spearman correlation between the Kurtzke EDSS and the relative expression of miR-337-3p in the CLIMB cohort. (B) Transportability phase: Spearman correlation between the EDSS and the relative expression of miR-337-3p across all MS centers. Number of patients with MS expressing hsa-miR-337-3p; mean MS = the mean expression value of hsa-miR-337-3p; SD MS = the SD from the mean of the expression value of hsa-miR-337-3p. (C) Differential relative expression of hsa-miR-337-3p in patients with RRMS compared with patients with SPMS in the CLIMB cohort, using LNA-based qPCR. Abbreviations: AMIR = AUBMC-Multiple Sclerosis Interdisciplinary Research; CLIMB = Comprehensive Longitudinal Investigation of Multiple Sclerosis; EDSS = Expanded Disability Status Scale; LNA = locked nucleic acid; RR = relapsing-remitting; SP = secondary progressive; STOPMS II = Stockholm Prospective Assessment of Multiple Sclerosis II cohort.</p>
</caption>
<graphic xlink:href="NEURIMMINFL2017015800f1"></graphic>
</fig>
<p>In addition, we found that in the CLIMB cohort SPMS patients have significantly decreased (<italic>p</italic> = 0.01) expression of hsa-miR-337-3p compared with the patients with RRMS (<xref ref-type="fig" rid="F1">figure, C</xref>). The comparison between patients with SPMS and RRMS in the other 3 international cohorts showed a similar reduction in the expression of hsa-miR-337-3p in patients with SPMS compared with those with RRMS in 3 of the 4 cohorts (EPIC, AMIR, and CLIMB) (figure e-6, <ext-link ext-link-type="uri" xlink:href="http://links.lww.com/NXI/A63">links.lww.com/NXI/A63</ext-link>).</p>
</sec>
</sec>
<sec id="s3" sec-type="discussion">
<title>Discussion</title>
<p>In this study, we tested the differential expression of serum miRNAs and the performance of prediction models in samples from untreated patients with MS. The study aimed at testing both reproducibility in CLIMB and transportability in multiple international centers. In our reproducibility phase cohort, we validated the differential expression of hsa-miR-484 in patients with MS as compared to HC (FDR &lt; 0.05). In addition, we found an excellent performance of the prediction model including hsa-let-7c-5p and hsa-miR-452-5p discriminating MS from HC with an AUC of 0.85. hsa-miR-484 is a known factor in the regulation of neural progenitor cells and its decreased expression causes dysregulated synaptogenesis and is linked to neurodevelopmental conditions including epilepsy, autism, and hyperactivity<sup><xref ref-type="bibr" rid="R12">12</xref></sup>; hence, its increased expression in MS patients' sera might actually reflect the activation of neurogenesis pathways as part of an ongoing repair process.</p>
<p>Although no single miRNA was identified to be differentially expressed in all 4 cohorts when comparing SPMS vs HC, we found that the expression levels of hsa-miR-486-5p, hsa-miR-320a, hsa-miR-320b, and hsa-miR-320c were significantly upregulated in at least 2 independent international cohorts (<xref ref-type="table" rid="T4">table 4</xref>). Increased expression of hsa-miR-320a, hsa-miR-320b, and hsa-miR-320c also appears relevant to MS pathophysiology, and overexpression of miR-320 was found in MS lesions.<sup><xref ref-type="bibr" rid="R13">13</xref></sup> Multiple hsa-miR-320 targets previously reported could be involved in MS progression and in other diseases, such as cancer. Some of these targets include <italic>CD71, MCL-1, MMP-9, NRP1, HDAC4, B-catenin</italic>, and <italic>MAPK</italic>.<sup><xref ref-type="bibr" rid="R14">14</xref><xref ref-type="bibr" rid="R15">–</xref><xref ref-type="bibr" rid="R21">21</xref></sup> In this regard, the effect of hsa-miR-320 on MS pathogenesis is likely contextual, depending on the expression levels of the particular targets and the levels of this miRNA in specific cell types. One intriguing target for hsa-miR-320 is the proangiogenic <italic>NRP1</italic> in oral cancer.<sup><xref ref-type="bibr" rid="R17">17</xref></sup>
<italic>NRP1</italic> is highly involved in regulatory T-cell development, and it has been reported that <italic>NRP1</italic> knockout mice exhibit a more Th17-like phenotype.<sup><xref ref-type="bibr" rid="R22">22</xref></sup> This would suggest a pathogenic role for hsa-miR-320 in MS pathophysiology. However, when considering the other potential targets, it appears that hsa-miR-320 could also serve a protective role in MS.<sup><xref ref-type="bibr" rid="R23">23</xref><xref ref-type="bibr" rid="R24">–</xref><xref ref-type="bibr" rid="R29">29</xref></sup> Of interest, differential expression of hsa-miR-320 is not unique to MS; we also found it to be significantly increased in the sera of patients with Alzheimer disease (AD) and asthma, whereas it was decreased in the sera of patients with amyotrophic lateral sclerosis (ALS) in comparison to HC samples (unpublished data and Raheja et al<sup><xref ref-type="bibr" rid="R30">30</xref></sup>).</p>
<p>We discovered that hsa-miR-337-3p and hsa-miR-199a-5p negatively correlated with patient disability (EDSS). The correlation of hsa-miR-199a-5p expression to the EDSS was observed in samples from 2 independent centers. The modest negative correlation of hsa-miR-337-3p with the EDSS was corroborated in 3 independent MS cohorts. In addition, the expression of hsa-miR-337-3p was found to be downregulated in patients with AD compared with healthy individuals, but was not differentially expressed in other diseases including asthma, rheumatoid arthritis (RA), and ALS (unpublished data). Our recent study on the correlation of MRI parameters to circulating miRNA expression also showed that the decreased expression of hsa-miR-337-3p is correlated with increased T1/T2 lesion load (Spearman correlation coefficient = −0.39; <italic>p</italic> = 0.012).<sup><xref ref-type="bibr" rid="R31">31</xref></sup> Thus, hsa-miR-337-3p is a potential biomarker candidate for MS disease progression. Of interest, it has been reported that hsa-miR-337-3p targets <italic>RAP1A</italic> in cancer.<sup><xref ref-type="bibr" rid="R32">32</xref></sup> As <italic>RAP1A</italic> is a well-established major component of integrin activation,<sup><xref ref-type="bibr" rid="R33">33</xref></sup> these findings points toward a potential role of hsa-miR-337-3p to serve as a biomarker for prediction of therapy response to natalizumab, an α4β1-integrin inhibitor.<sup><xref ref-type="bibr" rid="R34">34</xref></sup></p>
<p>Some limitations encountered in this study include sample size, modest effect size of the reported findings, patient heterogeneity, and intercenter differences in patient selection and sample preparation and storage. Although we were able to confirm the transportability of several miRNAs in this international multicenter study population, we were also surprised that only few miRNAs were corroborated in all 4 centers. We believe that the inability to observe differences across all cohorts is likely attributed to these aforementioned limitations, in particular the low power of the study, especially considering the number of multiple comparisons. At the same time, we performed the analysis using all available samples rather than performing an a priori power calculation to determine the correct sample size. The heterogeneity of the population can be overcome in future studies by increasing the sample size across all comparison groups and using a standard procedure for patient's sample collection and storage. A sample size of 124 would be required to have 80% power to detect the all the differences observed in <xref ref-type="table" rid="T2">table 2</xref> using a 2-sample <italic>t</italic>-test.</p>
<p>We were also unable to validate any differentially expressed miRNAs in the RRMS population across multiple centers. Notably, there is a higher variability in the EDSS scores of the patients with RRMS collected from multiple centers (<xref ref-type="table" rid="T1">table 1</xref>).</p>
<p>This is an attempt to examine the potential of miRNAs as biomarkers in an international multicenter setting for the diagnosis and correlation with disability in MS. It is also an attempt to build a prediction model in a validation phase after a training phase and a discovery phase. We found a promising candidate (hsa-miR-337-3p) to be used to identify a progression state that has great potential for translation to a clinical setting. Altogether, our work on circulating miRNA biomarkers is likely to help promote the development of novel tools for noninvasive diagnosis and therapeutic prognosis for MS.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="supplementary-material">
<p>Class of Evidence: <ext-link ext-link-type="uri" xlink:href="http://NPub.org/coe">NPub.org/coe</ext-link></p>
</fn>
</fn-group>
<sec sec-type="contributions">
<title>Author contributions</title>
<p content-type="contributions">R. Keren: drafting the manuscript for content, study concept and design, analysis and interpretation of data, and acquisition of data. B.C. Healy: drafting the manuscript for content, study concept, statistical analysis, and interpretation of data. A. Paul: analysis or interpretation of data, acquisition of data, and revising the manuscript for content. C. Diaz-Cruz: acquisition of data and revising the manuscript for content. M. A. Mazzola and R. Raheja: revising the manuscript for content. B. I. Glanz: design and patient selection. P. Kivisakk, T. Chitnis, M. Jagodic, F. Piehl, T. Olsson, M. Khademi, S. Hauser, J. Oksenberg, and S. J. Khoury: design, patient selection, and collection. H. L. Weiner: revising the manuscript for content, study concept and design, study supervision and coordination, and obtaining funding. R. Gandhi: drafting and revising the manuscript for content, study concept and design, analysis and interpretation of data, study supervision and coordination, and obtaining funding.</p>
</sec>
<sec sec-type="funding">
<title>Study funding</title>
<p content-type="funding">This study was funded by the National MS Society and by NIH common funds via NCATS UH2/UH3 grant TR000890.</p>
</sec>
<sec sec-type="disclosure">
<title>Disclosure</title>
<p content-type="disclosure">K. Regev served on the scientific advisory boards of Merck, Sanofi, and Biogen and received travel funding from Merck, Roche, and Biogen. B.C. Healy served on the scientific advisory board of Biogen; served on the editorial board of <italic>Statistical Methods in Medical Research</italic>; and received research support from Merck Serono, Novartis, Genzyme, Verily life Sciences, and NIH. A. Paul reports no disclosures. C. Diaz-Cruz received research support from Merck Serono and Verily Life Sciences. M.A. Mazzola reports no disclosures. R. Raheja reports no disclosures. B. Glanz received research support from Merck Serono, Verily Life Sciences, NIH, Brigham Research Institute, and NMSS. P. Kivisakk received research support from Genentech, Sanofi Genzyme, and Verily Life Sciences. T. Chitnis served on the scientific advisory boards of Novartis and Sanofi Genzyme; consulted for Biogen, Celgene, Novartis, and Sanofi Genzyme; and received research support from EMD Serono, Verily, NMSS, The Peabody Foundation, the Consortium for MS Centers, and the Guthy-Jackson Charitable Foundation. M. Jagodic served on the editorial board of <italic>Physiologic Genomics</italic>; served as an Associate Editor of <italic>Frontiers in Neurology</italic>; and received research support from AstraZeneca, The Swedish Research Council, Stockholm County Council, Karolinska Institute, The Swedish Association for Persons with Neurologic Disability, The Swedish Brain Foundation, The Swedish Medical Society, and Petrus and Augusta Hedlunds Foundation. F. Piehl served on the scientific advisory board of Praxel/Chugai and received research support from Biogen, Novartis, Genzyme, Swedish Medical Research Council, and PCORI. T. Olsson served on the scientific advisory boards of Biogen, Genzyme, Merck, and Novartis; received travel funding and/or speaker honoraria from Novartis, Biogen, Genzyme, and Merck; served as coeditor of <italic>Current Opinion in Immunology</italic>; and received research support from Merck, Biogen, Genzyme/Sanofi, Novartis, Roche, Merck, Bayer Schering, Aventis, Biogen, AstraZeneca, The Swedish Research Council, Swedish Brain Foundation, Knut and Alice Wallenberg Foundation, Swedish Research Council, and Margaretha af Ugglas Foundation. M. Khademi reports no disclosures. S. Hauser served on the scientific advisory boards of Symbiotix, Annexon, Bionure, Molecular Stethoscope, Alector, and Neurona; received travel funding from F. Hoffmann La Roche; receives publishing royalties from McGraw-Hill Education; received writing support from F. Hoffmann La Roche; and received research support from the NIH, NMSS, and Conrad N. Hilton Foundation. H. Oksenberg served on the editorial board of <italic>Genes and Immunity</italic> and received research support from Genentech, NIH/NIAID, NIH/NINDS, University of Miami, and NMSS. S. Khoury served as an Associate Editor of <italic>Annals of Neurology</italic>, a section editor of <italic>Clinical Immunology</italic>, and editorial board member of <italic>Treatment Options in Neurology</italic> and <italic>MS Journal</italic> and received research support from Novartis. H.L. Weiner served on the scientific advisory board of The Guthy-Jackson Charitable Foundation, Teva, Biogen, Novartis, Sanofi-Aventis, Tilos, CBridge Capital, Genentech, Genzyme, vTv Therapeutics, and MedDay; consulted for Biodextris, Biogen, Novartis, Serono, Teva, Sanofi Genzme, Tilos, Tiziana Life Sciences, vTv Therapeutics, MedDay, Genentech, and CBridge Capital; and received research support from EMD Serono, Google Life Sciences, NIH, and NMSS. R. Gandhi is employed by Sanofi Genzyme and received research support from the NIH and Race to Erase MS. Full disclosure form information provided by the authors is available with the full text of this article at <ext-link ext-link-type="uri" xlink:href="http://nn.neurology.org/lookup/doi/10.1212/NXI.0000000000000491">Neurology.org/NN</ext-link>.</p>
</sec>
<glossary>
<title>Glossary</title>
<def-list>
<def-item>
<term id="G1">AD</term>
<def>
<p>Alzheimer disease</p>
</def>
</def-item>
<def-item>
<term id="G2">AMIR</term>
<def>
<p>AUBMC Multiple Sclerosis Interdisciplinary Research</p>
</def>
</def-item>
<def-item>
<term id="G3">ALS</term>
<def>
<p>amyotrophic lateral sclerosis</p>
</def>
</def-item>
<def-item>
<term id="G4">AUBMC</term>
<def>
<p>American University of Beirut Medical Center</p>
</def>
</def-item>
<def-item>
<term id="G5">AUC</term>
<def>
<p>Area under curve</p>
</def>
</def-item>
<def-item>
<term id="G6">AUCROC</term>
<def>
<p>area under the ROC curve</p>
</def>
</def-item>
<def-item>
<term id="G7">CLIMB</term>
<def>
<p>Comprehensive Longitudinal Investigation of Multiple Sclerosis</p>
</def>
</def-item>
<def-item>
<term id="G8">EPIC study</term>
<def>
<p>Expression, Proteomics, Imaging, Clinical study</p>
</def>
</def-item>
<def-item>
<term id="G9">FDR</term>
<def>
<p>false discovery rate</p>
</def>
</def-item>
<def-item>
<term id="G10">HC</term>
<def>
<p>healthy control</p>
</def>
</def-item>
<def-item>
<term id="G11">miRNA</term>
<def>
<p>microRNA</p>
</def>
</def-item>
<def-item>
<term id="G12">RA</term>
<def>
<p>rheumatoid arthritis</p>
</def>
</def-item>
<def-item>
<term id="G13">RR</term>
<def>
<p>relapsing-remitting</p>
</def>
</def-item>
<def-item>
<term id="G14">RRMS</term>
<def>
<p>relapsing-remitting multiple sclerosis</p>
</def>
</def-item>
<def-item>
<term id="G15">SPMS</term>
<def>
<p>secondary progressive multiple sclerosis</p>
</def>
</def-item>
<def-item>
<term id="G16">STOPMS II</term>
<def>
<p>Stockholm Prospective Assessment of Multiple Sclerosis</p>
</def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="R1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Compston</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Coles</surname><given-names>A</given-names></name></person-group>
<article-title>Multiple sclerosis</article-title>. <source/>Lancet
<year>2008</year>;<volume>372</volume>:<fpage>1502</fpage>–<lpage>1517</lpage>.<pub-id pub-id-type="pmid">18970977</pub-id></mixed-citation>
</ref>
<ref id="R2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiner</surname><given-names>HL</given-names></name></person-group>
<article-title>Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease</article-title>. <source/>Arch Neurol
<year>2004</year>;<volume>61</volume>:<fpage>1613</fpage>–<lpage>1615</lpage>.<pub-id pub-id-type="pmid">15477521</pub-id></mixed-citation>
</ref>
<ref id="R3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gholipour</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Healy</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Baruch</surname><given-names>NF</given-names></name>, <name name-style="western"><surname>Weiner</surname><given-names>HL</given-names></name>, <name name-style="western"><surname>Chitnis</surname><given-names>T</given-names></name></person-group>
<article-title>Demographic and clinical characteristics of malignant multiple sclerosis</article-title>. <source/>Neurology
<year>2011</year>;<volume>76</volume>:<fpage>1996</fpage>–<lpage>2001</lpage>.<pub-id pub-id-type="pmid">21646626</pub-id></mixed-citation>
</ref>
<ref id="R4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amato</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Zipoli</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Goretti</surname><given-names>B</given-names></name>, <etal>et al</etal></person-group>
<article-title>Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort</article-title>. <source/>J Neurol
<year>2006</year>;<volume>253</volume>:<fpage>1054</fpage>–<lpage>1059</lpage>.<pub-id pub-id-type="pmid">16609810</pub-id></mixed-citation>
</ref>
<ref id="R5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gandhi</surname><given-names>R</given-names></name></person-group>
<article-title>miRNA in multiple sclerosis: search for novel biomarkers</article-title>. <source/>Mult Scler
<year>2015</year>;<volume>21</volume>:<fpage>1095</fpage>–<lpage>1103</lpage>.<pub-id pub-id-type="pmid">25921051</pub-id></mixed-citation>
</ref>
<ref id="R6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qu</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>B</given-names></name></person-group>
<article-title>MicroRNAs in autoimmune diseases</article-title>. <source/>Biomed Res Int
<year>2014</year>;<volume>2014</volume>:<fpage>527895</fpage>.<pub-id pub-id-type="pmid">24991561</pub-id></mixed-citation>
</ref>
<ref id="R7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jagot</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Davoust</surname><given-names>N</given-names></name></person-group>
<article-title>Is it worth considering circulating microRNAs in multiple sclerosis?</article-title>
<source/>Front Immunol
<year>2016</year>;<volume>7</volume>:<fpage>129</fpage>.<pub-id pub-id-type="pmid">27092141</pub-id></mixed-citation>
</ref>
<ref id="R8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sondergaard</surname><given-names>HB</given-names></name>, <name name-style="western"><surname>Hesse</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Krakauer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sorensen</surname><given-names>PS</given-names></name>, <name name-style="western"><surname>Sellebjerg</surname><given-names>F</given-names></name></person-group>
<article-title>Differential microRNA expression in blood in multiple sclerosis</article-title>. <source/>Mult Scler
<year>2013</year>;<volume>19</volume>:<fpage>1849</fpage>–<lpage>1857</lpage>.<pub-id pub-id-type="pmid">23773985</pub-id></mixed-citation>
</ref>
<ref id="R9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Regev</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Paul</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Healy</surname><given-names>B</given-names></name>, <etal>et al</etal></person-group>
<article-title>Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis</article-title>. <source/>Neurol Neuroimmunol Neuroinflamm
<year>2016</year>;<volume>3</volume>:<fpage>e267</fpage>. doi: <pub-id pub-id-type="doi">10.1212/NXI.0000000000000267</pub-id>.<pub-id pub-id-type="pmid">27606352</pub-id></mixed-citation>
</ref>
<ref id="R10">
<label>10.</label>
<mixed-citation publication-type="journal"><collab>University of California SFMSET</collab>, <person-group person-group-type="author"><name name-style="western"><surname>Cree</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Gourraud</surname><given-names>PA</given-names></name>, <etal>et al</etal></person-group>
<article-title>Long-term evolution of multiple sclerosis disability in the treatment era</article-title>. <source/>Ann Neurol
<year>2016</year>;<volume>80</volume>:<fpage>499</fpage>–<lpage>510</lpage>.<pub-id pub-id-type="pmid">27464262</pub-id></mixed-citation>
</ref>
<ref id="R11">
<label>11.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benjamini</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Hochberg</surname><given-names>Y</given-names></name></person-group>
<article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title>. <source/>J Royal Stat Soc
<year>1995</year>;<volume>57</volume>:<fpage>289</fpage>–<lpage>300</lpage>.</mixed-citation>
</ref>
<ref id="R12">
<label>12.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujitani</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fujiki</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Fujihara</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yamashita</surname><given-names>T</given-names></name></person-group>
<article-title>A chromosome 16p13.11 microduplication causes hyperactivity through dysregulation of miR-484/protocadherin-19 signaling</article-title>. <source/>Mol Psychiatry
<year>2017</year>;<volume>22</volume>:<fpage>364</fpage>–<lpage>374</lpage>.<pub-id pub-id-type="pmid">27378146</pub-id></mixed-citation>
</ref>
<ref id="R13">
<label>13.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Junker</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Krumbholz</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Eisele</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47</article-title>. <source/>Brain
<year>2009</year>;<volume>132</volume>:<fpage>3342</fpage>–<lpage>3352</lpage>.<pub-id pub-id-type="pmid">19952055</pub-id></mixed-citation>
</ref>
<ref id="R14">
<label>14.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Qiu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>L</given-names></name>, <etal>et al</etal></person-group>
<article-title>MiR-320a is downregulated in patients with myasthenia gravis and modulates inflammatory cytokines production by targeting mitogen-activated protein kinase 1</article-title>. <source/>J Clin Immunol
<year>2013</year>;<volume>33</volume>:<fpage>567</fpage>–<lpage>576</lpage>.<pub-id pub-id-type="pmid">23196978</pub-id></mixed-citation>
</ref>
<ref id="R15">
<label>15.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>HX</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>W</given-names></name>, <etal>et al</etal></person-group>
<article-title>The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma</article-title>. <source/>J Hepatol
<year>2009</year>;<volume>50</volume>:<fpage>358</fpage>–<lpage>369</lpage>.<pub-id pub-id-type="pmid">19070389</pub-id></mixed-citation>
</ref>
<ref id="R16">
<label>16.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chou</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Shahi</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Werb</surname><given-names>Z</given-names></name></person-group>
<article-title>microRNA-mediated regulation of the tumor microenvironment</article-title>. <source/>Cell Cycle
<year>2013</year>;<volume>12</volume>:<fpage>3262</fpage>–<lpage>3271</lpage>.<pub-id pub-id-type="pmid">24036551</pub-id></mixed-citation>
</ref>
<ref id="R17">
<label>17.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>YY</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>YL</given-names></name>, <name name-style="western"><surname>Jao</surname><given-names>YC</given-names></name>, <name name-style="western"><surname>Hsieh</surname><given-names>IS</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>KC</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>TM</given-names></name></person-group>
<article-title>miR-320 regulates tumor angiogenesis driven by vascular endothelial cells in oral cancer by silencing neuropilin 1</article-title>. <source/>Angiogenesis
<year>2014</year>;<volume>17</volume>:<fpage>247</fpage>–<lpage>260</lpage>.<pub-id pub-id-type="pmid">24114198</pub-id></mixed-citation>
</ref>
<ref id="R18">
<label>18.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukushima</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Taki</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ise</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Horii</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Yoshida</surname><given-names>T</given-names></name></person-group>
<article-title>MicroRNAs expression in the ethylene glycol monomethyl ether-induced testicular lesion</article-title>. <source/>J Toxicol Sci
<year>2011</year>;<volume>36</volume>:<fpage>601</fpage>–<lpage>611</lpage>.<pub-id pub-id-type="pmid">22008535</pub-id></mixed-citation>
</ref>
<ref id="R19">
<label>19.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schaar</surname><given-names>DG</given-names></name>, <name name-style="western"><surname>Medina</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Moore</surname><given-names>DF</given-names></name>, <name name-style="western"><surname>Strair</surname><given-names>RK</given-names></name>, <name name-style="western"><surname>Ting</surname><given-names>Y</given-names></name></person-group>
<article-title>miR-320 targets transferrin receptor 1 (CD71) and inhibits cell proliferation</article-title>. <source/>Exp Hematol
<year>2009</year>;<volume>37</volume>:<fpage>245</fpage>–<lpage>255</lpage>.<pub-id pub-id-type="pmid">19135902</pub-id></mixed-citation>
</ref>
<ref id="R20">
<label>20.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsieh</surname><given-names>IS</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>KC</given-names></name>, <name name-style="western"><surname>Tsai</surname><given-names>YT</given-names></name>, <etal>et al</etal></person-group>
<article-title>MicroRNA-320 suppresses the stem cell-like characteristics of prostate cancer cells by downregulating the Wnt/beta-catenin signaling pathway</article-title>. <source/>Carcinogenesis
<year>2013</year>;<volume>34</volume>:<fpage>530</fpage>–<lpage>538</lpage>.<pub-id pub-id-type="pmid">23188675</pub-id></mixed-citation>
</ref>
<ref id="R21">
<label>21.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Chakrabarti</surname><given-names>S</given-names></name></person-group>
<article-title>miR-320 regulates glucose-induced gene expression in diabetes</article-title>. <source/>ISRN Endocrinol
<year>2012</year>;<volume>2012</volume>:<fpage>549875</fpage>.<pub-id pub-id-type="pmid">22900199</pub-id></mixed-citation>
</ref>
<ref id="R22">
<label>22.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solomon</surname><given-names>BD</given-names></name>, <name name-style="western"><surname>Mueller</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Chae</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Alabanza</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Bynoe</surname><given-names>MS</given-names></name></person-group>
<article-title>Neuropilin-1 attenuates autoreactivity in experimental autoimmune encephalomyelitis</article-title>. <source/>Proc Natl Acad Sci U S A
<year>2011</year>;<volume>108</volume>:<fpage>2040</fpage>–<lpage>2045</lpage>.<pub-id pub-id-type="pmid">21245328</pub-id></mixed-citation>
</ref>
<ref id="R23">
<label>23.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sellebjerg</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Krakauer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Limborg</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>Endogenous and recombinant type I interferons and disease activity in multiple sclerosis</article-title>. <source/>PLoS One
<year>2012</year>;<volume>7</volume>:<fpage>e35927</fpage>.<pub-id pub-id-type="pmid">22701554</pub-id></mixed-citation>
</ref>
<ref id="R24">
<label>24.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mandel</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Paperna</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Miller</surname><given-names>A</given-names></name></person-group>
<article-title>Aberrant expression of the apoptosis-related proteins BAK and MCL1 in T cells in multiple sclerosis</article-title>. <source/>J Neuroimmunol
<year>2012</year>;<volume>244</volume>:<fpage>51</fpage>–<lpage>56</lpage>.<pub-id pub-id-type="pmid">22257632</pub-id></mixed-citation>
</ref>
<ref id="R25">
<label>25.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aung</surname><given-names>LL</given-names></name>, <name name-style="western"><surname>Mouradian</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Dhib-Jalbut</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Balashov</surname><given-names>KE</given-names></name></person-group>
<article-title>MMP-9 expression is increased in B lymphocytes during multiple sclerosis exacerbation and is regulated by microRNA-320a</article-title>. <source/>J Neuroimmunol
<year>2015</year>;<volume>278</volume>:<fpage>185</fpage>–<lpage>189</lpage>.<pub-id pub-id-type="pmid">25468268</pub-id></mixed-citation>
</ref>
<ref id="R26">
<label>26.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faraco</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Cavone</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Chiarugi</surname><given-names>A</given-names></name></person-group>
<article-title>The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis</article-title>. <source/>Mol Med
<year>2011</year>;<volume>17</volume>:<fpage>442</fpage>–<lpage>447</lpage>.<pub-id pub-id-type="pmid">21373721</pub-id></mixed-citation>
</ref>
<ref id="R27">
<label>27.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guan</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Nagarkatti</surname><given-names>PS</given-names></name>, <name name-style="western"><surname>Nagarkatti</surname><given-names>M</given-names></name></person-group>
<article-title>CD44 Reciprocally regulates the differentiation of encephalitogenic Th1/Th17 and Th2/regulatory T cells through epigenetic modulation involving DNA methylation of cytokine gene promoters, thereby controlling the development of experimental autoimmune encephalomyelitis</article-title>. <source/>J Immunol
<year>2011</year>;<volume>186</volume>:<fpage>6955</fpage>–<lpage>6964</lpage>.<pub-id pub-id-type="pmid">21551360</pub-id></mixed-citation>
</ref>
<ref id="R28">
<label>28.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>GX</given-names></name>, <name name-style="western"><surname>Guan</surname><given-names>Y</given-names></name></person-group>
<article-title>Wnt signaling in remyelination in multiple sclerosis: friend or foe?</article-title>
<source/>Mol Neurobiol
<year>2014</year>;<volume>49</volume>:<fpage>1117</fpage>–<lpage>1125</lpage>.<pub-id pub-id-type="pmid">24243343</pub-id></mixed-citation>
</ref>
<ref id="R29">
<label>29.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krementsov</surname><given-names>DN</given-names></name>, <name name-style="western"><surname>Thornton</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Teuscher</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Rincon</surname><given-names>M</given-names></name></person-group>
<article-title>The emerging role of p38 mitogen-activated protein kinase in multiple sclerosis and its models</article-title>. <source/>Mol Cel Biol
<year>2013</year>;<volume>33</volume>:<fpage>3728</fpage>–<lpage>3734</lpage>.</mixed-citation>
</ref>
<ref id="R30">
<label>30.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raheja</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Regev</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Healy</surname><given-names>BC</given-names></name>, <etal>et al</etal></person-group>
<article-title>Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis</article-title>. <source/>Muscle Nerve Epub 2018 Feb 21. doi: <pub-id pub-id-type="doi">10.1002/mus.26106</pub-id>.</mixed-citation>
</ref>
<ref id="R31">
<label>31.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Regev</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Healy</surname><given-names>BC</given-names></name>, <name name-style="western"><surname>Khalid</surname><given-names>F</given-names></name>, <etal>et al</etal></person-group>
<article-title>Association between serum MicroRNAs and magnetic resonance imaging measures of multiple sclerosis severity</article-title>. <source/>JAMA Neurol
<year>2017</year>;<volume>74</volume>:<fpage>275</fpage>–<lpage>285</lpage>.<pub-id pub-id-type="pmid">28114622</pub-id></mixed-citation>
</ref>
<ref id="R32">
<label>32.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Subauste</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>DeSevo</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>
<article-title>miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers</article-title>. <source/>PLoS One
<year>2012</year>;<volume>7</volume>:<fpage>e39167</fpage>.<pub-id pub-id-type="pmid">22723956</pub-id></mixed-citation>
</ref>
<ref id="R33">
<label>33.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimonaka</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Katagiri</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Nakayama</surname><given-names>T</given-names></name>, <etal>et al</etal></person-group>
<article-title>Rap1 translates chemokine signals to integrin activation, cell polarization, and motility across vascular endothelium under flow</article-title>. <source/>J Cel Biol
<year>2003</year>;<volume>161</volume>:<fpage>417</fpage>–<lpage>427</lpage>.</mixed-citation>
</ref>
<ref id="R34">
<label>34.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Engelhardt</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Kappos</surname><given-names>L</given-names></name></person-group>
<article-title>Natalizumab: targeting alpha4-integrins in multiple sclerosis</article-title>. <source/>Neurodegener Dis
<year>2008</year>;<volume>5</volume>:<fpage>16</fpage>–<lpage>22</lpage>.<pub-id pub-id-type="pmid">18075270</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>